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Abstract
Ceftobiprole is a broad-spectrum cephalosporin. The objective of this study was to test the hypothesis that the phar-
macokinetics (PK) and exposure of ceftobiprole in Asian subjects are similar to those in non-Asian subjects. Three
approaches were followed. The first compared the individual PK estimates between the 2 subgroups derived from a
population PK model previously built. Next, it was determined whether “Asian subject” was a significant covariate.
Finally, a pharmacodynamic analysis was performed by comparing measures of exposure and target attainment. No sig-
nificant differences were found between PK parameter estimates for Asian and non-Asian subjects, with median values
(range) for clearance of 4.82 L/h (2.12–10.47) and 4.97 L/h (0.493–20.6), respectively (P = .736). “Asian subject” was not
a significant covariate in the population PK model. There were no significant differences between the measures of ex-
posure. The geometric mean ratio for the fAUC was 1.022 (90%CI, 0.91–1.15), indicating bioequivalence. Taking a target
of 60% coverage of the dose interval, more than 90% of the population in both subgroups was adequately exposed. This
analysis demonstrated that there are no PK or pharmacodynamic differences between Asian and non-Asian subjects for
a ceftobiprole dose of 500 mg every 8 hours as a 2-hour infusion.
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Ceftobiprole, a broad-spectrum cephalosporin derived
from the prodrug ceftobiprole medocaril, is approved
in adults in Europe for the treatment of community-
acquired pneumonia and hospital-acquired pneumo-
nia, excluding ventilator-associated pneumonia.1 The
antimicrobial spectrum includes a wide range of
Gram-negative bacteria, as well as methicillin-resistant
Staphylococcus aureus and penicillin-resistant Strepto-
coccus pneumoniae.2,3
Before approval, the safety, efficacy, and pharma-
cokinetics (PK) of ceftobiprole were extensively studied
in global populations. However, it is known for some
drugs that the PK are different in specific populations
or are race dependent.4–7 For another cephalosporin,
cephalexin, it was shown that differences in peptide
transporter 2 polymorphism distribution exists be-
tween various populations. For cephalexin, these dif-
ferences did not result in relevant PK differences.8
This illustrates that PK differences between popula-
tions for cephalosporins may exist. Ceftobiprole is po-
tentially a weak substrate of the renal tubule cell uptake
transporters organic anion transporter 1 and organic
cation transporter 2. Therefore, it is mandatory in some
countries, including Asian countries, to show that the
dosing regimen chosen is adequate in subjects in these
specific countries before the drug can be registered.
Studies on ceftobiprole PK in Asian people living in
Asia are obligatory to prove that a dosing regimen sim-
ilar to that in non-Asian subjects can be used.
Ceftobiprole is not metabolized and is primarily
eliminated in its unchanged form by glomerular fil-
tration. While PK differences of ceftobiprole between
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Asian and non-Asian subjects are therefore unlikely, the
main objective of this study was to test the hypothe-
sis that the PK and pharmacodynamics (PD) of cefto-
biprole in Asian subjects are not significantly different
from those in non-Asian subjects. In addition to evalu-
ating whether differences exist in the PK of ceftobiprole
in Asians, particularly Asians of Chinese origin, to de-
termine whether dose adjustments would be required,
the analysis also serves to demonstrate that additional
clinical trials in Asian countries, commonly requested
by local authorities, are not useful and even superfluous.
To that purpose, we compared the PK parameter esti-
mates of Asian subjects and non-Asian subjects from a
population model we developed earlier.9 We also evalu-
ated whether the property “Asian” was significant as a
covariate in this PK model. Finally, we calculated dif-
ferent PK/PD indices for exposure for the 2 subgroups
to determine whether there were significant differences
in target attainment.
Materials and Methods
Asian and Non-Asian Population
A total of 47 Asian subjects and 153 non-Asian
subjects were included in the analysis. The PK data
included 29 Asian individuals from the phase 3 compli-
cated skin and soft tissue infection study (BAP00414,
NCT00210899) and 18 subjects from a PK study
published previously involving 171 patients with noso-
comial pneumonia.9 The BAP00414 phase 3 study
compared ceftobiprole to vancomycin plus ceftazidime
in the treatment of resistant S aureus skin and skin
structure infections, taking into account clinical cure
and safety.10 Ceftobiprole monotherapy was shown to
be as effective as vancomycin plus ceftazidime in these
patients. The non-Asian subjects were all from the lat-
ter study. Thus, the new dataset consisted of a total of
200 patients for the analysis. The term “Asian subjects”
refers to a subject of an Asian race treated at a clinical
study site in the People’s Republic of China, Taiwan,
or the Republic of Korea. All other subjects were from
various non-Asian countries (such as United States,
Argentina, Honduras, Brazil, Mexico, and Czech Re-
public). Of the non-Asian subjects, 78 individuals with
rich-sampling (7 samples or more) and of the Asian
subjects, 23 individuals with rich sampling were
included. Demographic data were included in the
database (age, weight, body mass index, and creatinine
clearance [CrCL], which was calculated using the
Cockcroft-Gault equation). All data were provided to
the authors by Basilea Pharmaceutica International
Ltd. Information on the individual study sites and the
Institutional Review Board is available in the supple-
mentary data file. The studies were in accordance with
the Declaration of Helsinki and all participants gave
written informed consent.
Ceftobiprole Administration, Sampling, and Concen-
trations
Ceftobiprole was administered intravenously in doses
of 500 mg infused over 2 hours every 8 hours. Blood
samples were drawn at different time points and con-
sisted of a median of 3 samples per patient (range 1–
7), mostly during multiple dosing intervals. The exact
sampling times were recorded and used in the analysis.
Immediately after sampling, the samples were kept on
ice and stored at −70°C until analysis.9
For the measurement of the concentrations of cefto-
biprole, liquid chromatography tandemmass spectrom-
etry was used, with a lower limit of quantification of 20
or 50 ng/mL in 2 different laboratories. The method-
ologies and controls used were comparable, mak-
ing it unlikely that structural differences between the
measurements of the 2 laboratories exist. Within every
run, a set of quality controls was included, covering the
entire range of the measurements. All relevant informa-
tion on the methodology from the original validation
reports is presented in the supplementary data.
Population PK Analysis
The population PK model of ceftobiprole has been
described before.9 Briefly, a 3-compartment model
with age as covariate on the volume of the central
compartment and CrCL as covariate on the systemic
clearance was developed using Compaq Visual FOR-
TRAN standard edition 6.6 (Compaq Computer
Corp., Euston, Texas) and the NONMEM software
package (version VI, release 2; Icon Development
Solutions, Ellicott City, Maryland). The model was
implemented in the NONMEM ADVAN5 subroutine
and the analysis was performed using the FOCE
method with INTERACTION.
The new dataset of 200 individuals was evaluated us-
ing the model. The criteria used to accept this model for
the new dataset were as follows: no systematic deviation
in the model fits or goodness-of-fit plots (visually in-
spected); no aberrant values in the basic structural PK
parameter estimates or in their respective confidence in-
tervals.
To determine whether the difference between Asian
and non-Asian subjects was a significant covariate in
the model, as an indication of potential PK differences
between Asian and non-Asian subjects, the covariate
“Asian”was incorporated into themodel using the same
method as for the other covariates. Briefly, all covari-
ates were tested one by one in the basic model and only
covariates with a significant improvement compared to
the basic model were used in further analysis. To select
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a covariate for further analysis, a level of significance of
0.05 was used (corresponding to a difference of at least
3.84 points in mean objective function value).
Exposure to Ceftobiprole in the Subgroups
Using individual PK parameter estimates from the fi-
nal population PK model or correlations between the
parameter estimates and the covariates (CrCL and
age) as described earlier,9 the exposure to ceftobip-
role was calculated individually for all subjects. Val-
ues for fraction of dosing interval the unbound (free)
drug concentration exceeds minimum inhibitory con-
centration (%fT>MIC), area under the unbound drug
concentration-time curve (fAUC), maximal unbound
drug concentration fCmax, and minimum unbound
drug concentration fCmin were derived using KINFUN
1.06 (Medimatics, Maastricht, the Netherlands). The
AUC presented is the AUC of a single dose in steady
state. The %fT>MIC was calculated for 4 fixed MIC val-
ues (MIC of 1, 2, 4, and 8 mg/L) for the dose of 500 mg
every 8 hours administered intravenously over 2 hours.
Protein binding of 16% was used in the analysis.11
Target Attainment Rates
The exposure to ceftobiprole was calculated for each in-
dividual for a range of fixedMIC values (0.5–32 mg/L),
by determining the %fT>MIC for each of the 200 pa-
tients in the analysis dataset, based on the individual
PK parameter estimates using KINFUN 1.06. The tar-
get attainment rate was calculated for a range of PK/PD
targets (%fT>MIC values from 30%–100% of the dosing
interval).
Statistical Analysis
Comparisons between groups were performed using the
Mann-Whitney test (2-tailed, P < .05) in GraphPad
prism v5.0 (Graphpad Inc, La Jolla, California). They
were calculated based on the median to avoid influence
of extreme outliers on the results. For the test of bioe-
quivalence, the geometric mean ratio of fAUC with its
90%CI was calculated using SAS version 9.3 (SAS In-
stitute Inc, Cary, North Carolina) using the TTest pro-
cedure. Results were interpreted following the US Food
and Drug Administration Statistical Approaches to Es-
tablishing Bioequivalence guidance, which states that
bioequivalence is shown if the 90%CI for the geometric
mean ratio falls between 0.8 and 1.25.12 A power cal-
culation with an α of 0.05 would yield statistical power
of 90% to detect a difference in %fT>MIC of 10% after
inclusion of 47 Asian subjects in a total sample of 200
individuals.
Results
Population and Demographics
The median values and the ranges for age, body weight,
body mass index, and CrCL of the 47 Asian and 153
non-Asian subjects are represented in Table 1. The val-
ues for the 2 covariates of the population PK model,
age and CrCL, were not significantly different between
the 2 subgroups (P = .657 and P = .553, respectively).
The median value for body weight for Asian subjects
was significantly lower compared with non-Asian sub-
jects (64 kg vs 75 kg, respectively; P = .0005), however,
the ranges of the 2 subgroups were overlapping. De-
spite the difference in weight between the 2 subgroups,
the body mass indices were similar, with median values
of 24.0 kg/m2 and 24.7 kg/m2 for Asian and non-Asian
subjects, respectively (P = .983).
Population PK Analysis
The dataset of the 200 patients was submitted to
the previously published model.9 The estimates of the
structural PK parameter with the coefficient of varia-
tion for the published and current analysis are shown
in Table 2. The current analysis did not result in aber-
rant values for the structural PK parameter estimates
and were comparable to the previous analysis.9 The
goodness-of-fit plots demonstrated a good model fit
and no deviation was introduced by adding patients
to the dataset. Based on the predefined criteria, we ac-
cepted this model in further analyses.
The results from the population PKmodel were used
to detect differences between the subgroups for several
PK parameters. None of the determined means of the
PK parameter estimates were significantly different be-
tween the subgroups, as is shown in Table 1.
The incorporation of the covariate “Asian” into the
basic model did not improve it significantly: the dif-
ference in mean objective function value for the model
with Asian as covariate on clearance and volume of dis-
tribution of central compartment compared to the ba-
sic model without other covariates was 0.002 and 0.099
points, respectively. The variability in clearance or vol-
umes of distribution did not decrease after implemen-
tation of this covariate, indicating a lack of difference
in PK between the 2 subgroups.
Exposure to Ceftobiprole in Asian vs Non-Asian
The exposure to ceftobiprole in the 2 subgroups, Asian
and non-Asian, was calculated for each of the PK/PD
indices (%fT>MIC, fAUC [single dose steady state],
fCmax, fCmin). The results of the comparison are shown
in Table 3 and a selection of the indices in shown in
Figure 1. The exposure of one of the non-Asian sub-
jects was extremely unrealistic (eg, fAUC of 30536),
while the mean fAUC was 100 and the median fAUC
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Table 1. Demographics and PK Parameter Estimates for Asian and Non-Asian Subjects
Asian subjects (n=47) Non-Asian subjects (n=153)
Parameter N Mean# SD Median
Min
value
Max
Value N Mean# SD Median
Min
value
Max
value p-value*
Age 47 51.6 16.6 52.0 19 78.0 153 50.6 20.3 51.0 17.0 92.0 0.657
Weight 47 67.6 13.6 64.0 51 100 152 74.8 13.7 75.0 40.0 115.0 0.0005
BMI 47 25.5 4.94 24.0 18.2 42.3 151 25.1 4.23 24.7 15.6 41.4 0.983
Creatinine clearance 47 106.1 37.6 99.0 39.0 194.5 144 111.5 67.9 107.0 11.8 612.1 0.553
CL 47 4.91 1.89 4.82 2.12 10.47 152 5.16 2.73 4.97 0.49 20.6 0.736
Vd1 47 15.3 6.16 15.3 7.51 43.8 152 18.4 14.1 14.6 6.21 138.2 0.658
Vdss 47 21.0 6.16 21.1 13.3 49.5 152 24.2 14.1 20.3 12.0 144.0 0.658
Vd(area) 47 32.8 8.5 30.1 19.7 63.7 152 36.1 16.1 31.8 14.4 144.8 0.193
T1/2 47 4.88 1.32 4.33 3.97 11.4 152 5.65 3.21 4.29 3.80 32.2 0.599
*p-value represents the significance between the median values of the Asian and non-Asian subjects. #arithmetic mean. Min value= minimum value
of the range; max value- maximum value of the range; SD standard deviation, N= number of subjects; BMI=body Mass index (kg/m2); CL=clearance
(L/h), Vd1 volume of distribution of the central compartment (L); Vdss= volume of distribution at steady state (L). Vd, (area) was calculated based on
the terminal half-life20
Table 2. PK Estimate Parameters of the Previously Published Model9 vs Current Analysis
Previously Published Model (N = 171)9 Current Analysis (N = 200)
Parameter Mean SE
Relative
SE (% SE) Mean SE
Relative
SE (% SE)
Clearance (L/h) 4.74 0.24 5.06 4.71 0.22 4.73
Vd1 (L) 15.5 1.26 8.13 15.4 1.21 7.86
Vd2 (L) 1.93 0.34 17.6 1.89 0.34 17.7
Vd3 (L) 3.76 1.18 31.4 3.86 1.15 29.8
Intercompartmental clearance (Vd1 and Vd2) (L/h) 0.37 0.11 29 0.36 0.11 30.4
Intercompartmental clearance (Vd1 and Vd3) (L/h) 3.05 1.83 60 3.09 1.76 57
Covariate creatinine clearance on clearance 0.0052 0.0011 21.2 0.0053 0.0011 20.1
Covariate age on Vd1 0.012 0.0015 13.1 0.011 0.0015 13
Table 3. Data of the Various Measures of Exposure for the Subgroups Asian and Non-Asian Subjects
Asian Subjects (n = 47) Non-Asian Subjects (n = 153)
Parameter N Meanb SD Median Min Value Max Value N Meanb SD Median Min Value Max Value Pa
fT>MIC = 1 47 100 0 100 100 100 152 99.6 2.68 100 78.2 100 NA
fT>MIC = 2 47 99.4 2.29 100 87.2 100 152 97.7 7.63 100 52.6 100 0.342
fT>MIC = 4 47 88.9 13.7 97.9 59.7 100 152 87.2 16.0 93.5 23.0 100 0.608
fT>MIC = 8 47 66.5 25.3 59.7 8.66 100 152 63.8 27.5 54.2 0.0 100 0.749
fAUC 47 117.6 46.4 103.7 47.7 235.8 152 135.9 116.5 100.7 24.3 1015 0.736
fCmax 47 23.2 5.90 22.9 8.82 36.8 152 24.6 13.0 23.0 5.95 95.8 0.585
fCminss 47 5.67 4.34 3.85 1.46 19.9 152 7.78 11.4 3.52 0.50 98.7 0.902
f, free, unbound fraction; NA, not available; SD, standard deviation.
aP value represents the significance between median values for the Asian and non-Asian subjects.
bArithmetic mean. Min value = minimum value of the range; max value = maximum value of the range.
was 135. This appeared to be the result of aberrant
PK estimates, which were based on a single concentra-
tion of 387 mg/L at approximately 6 hours after the
start of the infusion. This is most likely not correct,
therefore this individual was excluded from the analy-
sis. There is another high value for CrCL in the data.
This value is outside the range for which the CrCL
by using the Cockcroft-Gault equation is validated,
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Figure 1. Distribution of %fT>MIC = 4 mg/L, fAUC, fCmax, and fCminss in Asian (n = 47) and non-Asian (n = 152) subjects.
f, free, unbound fraction.
usually up to 90 mL/min. This high value indicates that
the CrCL was high, but the measurement is not precise.
No other values were excluded. There were no signif-
icant differences in medians between the 2 subgroups.
The values for the Asian subjects are within the range
for the non-Asian subjects. This indicates no significant
difference in exposure to ceftobiprole between Asian
and non-Asian subjects. A further analysis showed that
the geometric mean ratio for the fAUC of non-Asian
and Asian subjects was 1.022 (90%CI, 0.91–1.15),
indicating bioequivalence.
Target Attainment Rates
To determine whether the individuals in the 2 sub-
groups were treated appropriately and equally, target
attainment rates were compared. The target attainment
for the 2 subgroups is shown in Figure 2. There is no
difference in observed target attainment between Asian
and non-Asian subjects. For broad spectrum coverage
targeting %fT>MIC = 4 mg/L of 50% or 60% of the dos-
ing interval, the probability of target attainment was at
least 90% in both subgroups.
Discussion
Using several approaches, this analysis demonstrated
there are no differences in the PK of ceftobiprole
between Asian and non-Asian subjects. No signifi-
cant differences were detected in the structural PK
parameter estimates of the subgroups. Furthermore,
the implementation of “Asian” as a covariate in the
model did not improve the population model, indicat-
ing no difference between the Asian and non-Asian
subgroups. Finally, we demonstrated that both sub-
groups were similarly exposed to ceftobiprole and that
the probability of target attainment for Asian and
non-Asian subjects did not differ for the recommended
dosing regimen of 500 mg every 8 hours as a 2-hour
infusion. This is also supported by the geometric mean
ratio of fAUCand its 90%CI, indicating bioequivalence
between non-Asian and Asian subjects.
The subgroups were comparable for the main demo-
graphic parameters. The only significant demographic
parameter was body weight. Asian subjects had a lower
body weight compared with non-Asian subjects. How-
ever, the PK of ceftobiprole is primarily driven by renal
status, in this study estimated by CrCL. There was no
significant difference in CrCL between Asian and non-
Asian subjects. Difference in body weight was, there-
fore, unlikely to be of importance for renal elimination
of ceftobiprole. It is also in agreement with the finding
of no difference in exposure and %fT>MIC between the
2 populations. Because the exposure did not differ be-
tween the 2 populations, the difference in body weight
has no implications on recommended dose.
As for other cephalosporins, the PK/PD index that
correlated best with microbiological eradication and
clinical cure was %fT>MIC, as has been shown for
ceftobiprole previously, both in preclinical evidence13
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Figure 2. Observed target attainment rates for Asian (n = 47) and non-Asian (n = 152) subjects for targets of concentrations above
the MIC, ranging from 40%–100% of the dosing interval. f, free, unbound fraction; TA, target attainment.
and in human data.14 The exposure required to re-
sult in a likely favorable outcome is at least 45%
fT>MIC for ceftazidime15 and 50%-60% fT>MIC for
ceftobiprole.14 However, another study has shown that
in some cases, 30% fT>MIC is sufficient, in particular for
staphylococci.16 We therefore calculated the exposure
for fT>MIC to be 30%-100% and concluded that for all
these different targets, the exposure in the 2 subgroups
was comparable.
Because PK/PD indices other than %fT>MIC might
be of importance, these indices were also compared.
The total exposure to ceftobiprole is best represented
by fAUC/MIC and was found to be similar between the
2 subgroups. In general, the fCmax might be of impor-
tance for toxicity17 and was also found to be similar for
the 2 subgroups.
To determine clinical breakpoints, the European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) uses 50%–60% as a PK/PD target for
cephalosporins used to treat severe infections caused by
Gram-negative infections.18 For ceftobiprole, the EU-
CAST recently determined breakpoints: 4 mg/L for the
PK/PD breakpoint, 0.25 mg/L for Enterobacteriaceae,
2 mg/L for S aureus, and 0.5 mg/L for S pneumoniae.19
Taking a target attainment rate of 60% fT>MIC and the
most conservative breakpoint of 4 mg/L, both Asian
and non-Asian subjects reached the target in at least
90% of the cases.
Conclusion
There are no clinically relevant differences in expo-
sure to ceftobiprole in Asian subjects compared with
non-Asian subjects, therefore the dosing regimen as ap-
proved by the European Medicines Agency for its use
in Europe can also be used in Asia.
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